Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tjalling Bosse

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2026
Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellowsAndrej Cokan, Martina Aida Angeles, Houssein El Hajj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2017
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group InitiativeTine Cuppens, Daniela Annibali, An Coosemans, et al.
Molecular Cancer|September 29, 2014
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancerLorena Alonso-Alconada, Laura Muinelo-Romay, Kadri Madissoo, et al.
The Lancet. Oncology|July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 8, 2021
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 24, 2020
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]Paul A Cohen, Aime Powell, Steffen Böhm, et al.
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
NPJ Precision Oncology|August 30, 2025
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancerEsmee Koedoot, Dieudonné J van der Meer, Anne M van Altena, et al.
The Prostate|August 4, 2018
Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) modelsNora M Navone, Wytske M van Weerden, Robert L Vessella, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 25, 2026
Highlights from the 27th European Congress on Gynecological Oncology in Copenhagen: interview compilation of the ENYGO-IJGC editorial fellowsAndrej Cokan, Martina Aida Angeles, Houssein El Hajj, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2017
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group InitiativeTine Cuppens, Daniela Annibali, An Coosemans, et al.
Molecular Cancer|September 29, 2014
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancerLorena Alonso-Alconada, Laura Muinelo-Romay, Kadri Madissoo, et al.
The Lancet. Oncology|July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
Gynecologic Oncology|May 24, 2019
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient dataPaul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 8, 2021
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448Paul A Cohen, Aime Powell, Steffen Böhm, et al.
Gynecologic Oncology|February 24, 2020
Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]Paul A Cohen, Aime Powell, Steffen Böhm, et al.
The Lancet. Oncology|May 3, 2024
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trialsFamke C Wakkerman, Jiqing Wu, Hein Putter, et al.
NPJ Precision Oncology|August 30, 2025
Ex vivo 3D micro-tumour testing platform for predicting clinical response to platinum-based therapy in patients with high-grade serous ovarian cancerEsmee Koedoot, Dieudonné J van der Meer, Anne M van Altena, et al.
The Prostate|August 4, 2018
Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) modelsNora M Navone, Wytske M van Weerden, Robert L Vessella, et al.
Pageof 17